ketamine


Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

August 23rd, 2022 - Ryan Allway

Based on over 20 years of pioneering Yale University research, clinical development currently underway to create and develop viable and efficacious treatment alternatives for patients with major depressive disorder by leveraging the known pharmacology of ketamine and psychedelic-based therapeutics   SAN FRANCISCO, August 23, 2022–(BUSINESS WIRE)–Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious […]

Another Public Company First: Silo Wellness Opens Jamaican Ecotourism Psilocybin Microdosing Resort for the Psychedelic Curious; Shareholder Discounts for Psychedelic Vacations Available

August 23rd, 2022 - Ryan Allway

Springfield, Oregon–(Newsfile Corp. – August 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), a leading global psychedelics company, is pleased to announce that it has opened its first ecotourism microdosing psilocybin resort and retreat center at Go Natural Jamaica in Long Bay, Portland, Jamaica. “We have been bombarded […]

Irwin Naturals Completes Georgia Acquisition, Adds Two Ketamine Clinics to National Chain

August 8th, 2022 - Ryan Allway

The national chain of psychedelic mental-healthcare clinics growing rapidly LOS ANGELES, Aug. 08, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of two ketamine clinics in Georgia through an asset purchase of Invictus Clinics, LLC, which will be brought into the fast-growing national chain of psychedelic […]

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.

August 3rd, 2022 - Ryan Allway

TORONTO, Aug. 3, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. (“KetaMD”) (the “Transaction”). KetaMD is a U.S. based, privately-held, […]

Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

July 6th, 2022 - Ryan Allway

VANCOUVER, BC, July 6, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive license for the psychedelics sector for a novel delivery system for […]

Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program – Ketamine-Assisted Therapy for Alcohol Use Disorder

July 5th, 2022 - Ryan Allway

Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III Toronto, Ontario–(Newsfile Corp. – July 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), […]

Irwin Naturals Expands Operations into Northeast with Acquisition of Vermont-Based Clinic

June 17th, 2022 - Ryan Allway

Company continues national growth trajectory for Emergence clinics focusing on total wellness including the therapeutic use of ketamine   LOS ANGELES, June 17, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has entered into a binding agreement to acquire the assets of Hobie Fuerstman D O […]

TripSitter.Clinic Launches New App for At-Home Ketamine Therapy

June 3rd, 2022 - Ryan Allway

TORONTO, June 3, 2022 /CNW/ – TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter” or the “Company”), today announced the official launch of the TripSitter App, a simple and free App that makes it easy for users to access TripSitter Clinics’ services.   TripSitter.Clinic Launches New App for At-Home Ketamine Therapy (CNW Group/TripSitter Clinic Ltd.) CEO of TripSitter […]

Company Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

April 18th, 2022 - Ryan Allway

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has taken the next step in the execution of its ketamine clinic roll-up strategy – a move the Company says is motivated by an intention to become the world’s largest chain of psychedelic […]

Revitalist Increases Clinic Count to 10 with the Acquisition of a Virginia Ketamine Clinic

March 29th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 29, 2022–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that has it has entered into a definitive agreement (“Merger Agreement“) to acquire Alchemy Wellness (“Alchemy“) a ketamine clinic (“Acquisition“) located in Richmond, Virginia (“Virginia Clinic“). The Acquisition, which was previously […]

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

March 23rd, 2022 - Ryan Allway

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported Study results are adequate to give an effect size in powering a Phase 3 clinical study PharmaTher planning a Phase 3 clinical study to allow for FDA […]

Revitalist Executes on Mission to Build a National Network of Ketamine Clinics

January 28th, 2022 - Ryan Allway

Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through conventional treatments. While psilocybin, MDMA, and other psychedelic medicines remain in clinical trials, the […]

NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board

January 13th, 2022 - Ryan Allway

Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics   Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President […]

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

January 12th, 2022 - Ryan Allway

• Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe   NEW YORK, Jan. […]

Revitalist Increases Clinic Count to Nine With Closing of Florida Clinic Acquisition

January 12th, 2022 - Ryan Allway

  REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that it has executed an asset purchase agreement (“Agreement”) dated January 11, 2022, to acquire a Ketamine clinic located in Jacksonville, Florida (“Acquisition”). Revitalist had previously announced the Acquisition non-binding letter of intent on October […]

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

January 11th, 2022 - Ryan Allway

-Enrollment expected to begin in early 2022 – TORONTO, January 11, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™“, today announced that an Institutional Review Board (“IRB”) has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect […]

Revitalist Opens its Eighth Clinic in Washington, D.C.

January 10th, 2022 - Ryan Allway

VANCOUVER, British Columbia–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce it has opened its eighth psychedelic assisted psychotherapy (“PAP”) clinic located just outside of Washington, D.C. at 4833 Rugby Ave, STE 600, Bethesda, MD, 20814 (“Clinic”). “Bethesda has such a heavy military presence […]

Revitalist Executes on Vision to Become a Clinical Leader in Psychedelics

December 10th, 2021 - Ryan Allway

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms, with more […]

While Psychedelics Wait, Ketamine Revenues Roll On

November 30th, 2021 - Ryan Allway

The nature of the psychedelic market today means that public company investors are making largely speculative investments. Though there are plenty of studies demonstrating the efficacy of substances ranging from LSD to psilocybin to MDMA, the fact remains they are Schedule 1 controlled substances and have not been approved for therapeutic use. Companies seeking such […]

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

November 15th, 2021 - Ryan Allway

Positive topline results from COMP360’s Phase 2b study RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4 Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort Launch of atai Impact, a […]

Awakn Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry

November 4th, 2021 - Ryan Allway

Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) psychotherapy intervention study, which was the first controlled study […]

Silo Pharma’s Sponsored Research Agreement with Columbia Could Yield a New Alzheimer’s Disease Treatment

November 3rd, 2021 - Ryan Allway

Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet, despite significant investment in clinical trials, the FDA has only approved two types of […]

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

October 13th, 2021 - Ryan Allway

Achieving its second FDA orphan drug designation with ketamine. Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation. Seeking to enter Phase 2 clinical trial in 2022.   TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics […]

Ehave One of the First Companies to Pioneer the Collection of Certain Data Points, as well as to Seek to Understand How Ketamine Can Potentially Resolve Issues in the Brain Through a Process Called Neuroplasticity

October 12th, 2021 - Ryan Allway

MIAMI, Oct. 12, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is wholly-owned by KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), to develop the […]

Ketamine Offers Promise to Veterans with PTSD

September 24th, 2021 - Ryan Allway

  Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the general population. PTSD manifests in many ways, ranging from depression to chronic fatigue. The FDA’s […]

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

September 20th, 2021 - Ryan Allway

Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development, Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage   National Presence Will Bring Psychedelic Wellness Treatment to the Masses VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ – Delic Holdings Corp (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform today announced it […]

Ketamine One Engages Psychology & Counselling Services Group for IRP Health

September 15th, 2021 - Ryan Allway

PCSG to Provide Psychology, Therapy, Dietary and Other Mental Health Services for the Wholly-Owned Ketamine One Subsidiary VANCOUVER, British Columbia, Sept. 14, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health […]

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

September 10th, 2021 - Ryan Allway

BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine […]

Ketamine One to Deploy Cognetivity’s Integrated Cognitive Assessment Tool

September 1st, 2021 - Ryan Allway

Ketamine One and Cognetivity Also Sign LOI to Collaborate on Mental Health Assessment Tools VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased […]

Ketamine One Subsidiary IRP Health Expands With New Veteran-Focused Clinics

August 30th, 2021 - Ryan Allway

Integrated Rehab and Performance Re-Branded as IRP Health to Better Reflect its Planned Evolution into a Multidisciplinary Business VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) , a company focused on consolidating medical clinics and becoming a North American leader in mental […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading